Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Update January 2022

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Update January 2022. Oncology Fact Sheet Nr. 67.

[thumbnail of Oncology Fact Sheet Nr.67_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
757kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 300-378 Kidney
Language:	English
Series Name:	Oncology Fact Sheet Nr. 67
Deposited on:	12 Nov 2021 15:48
Last Modified:	12 Jan 2022 13:28

Repository Staff Only: item control page